AJ1-11095

· Ajax Therapeutics, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for AJ1-11095, covering 2026-03-27 to 2026-03-27. Get the full timeline:

Most recent: Clinical Trial Update: A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i) [Phase 1]

See pricing